{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:00:56Z","timestamp":1780423256256,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"DOI":"10.7759\/cureus.110131","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:05:46Z","timestamp":1780419946000},"source":"Crossref","is-referenced-by-count":0,"title":["Refractory and\/or Resistant Herpes Simplex Virus Mucocutaneous Infections in Adult Transplantation and Cellular Therapy Patients: A Single-Center Experience"],"prefix":"10.7759","author":[{"given":"Joseph I","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavio V","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele I","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaros J","family":"Lekakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Beitinjaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trent P","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa G","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna V","family":"Komanduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2025.106152","article-title":"Overview on the management of herpes simplex virus infections: current therapies and future directions","volume":"237","author":"Birkmann A","year":"2025","unstructured":"Birkmann A, Saunders R. Overview on the management of herpes simplex virus infections: current therapies and future directions. Antiviral Res. 2025, 237:106152. 10.1016\/j.antiviral.2025.106152","journal-title":"Antiviral Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2574","article-title":"Management of refractory\/resistant herpes simplex virus infections in haematopoietic stem cell transplantation recipients: a literature review","volume":"34","author":"Sall\u00e9e L","year":"2024","unstructured":"Sall\u00e9e L, Boutolleau D. Management of refractory\/resistant herpes simplex virus infections in haematopoietic stem cell transplantation recipients: a literature review. Rev Med Virol. 2024, 34:e2574. 10.1002\/rmv.2574","journal-title":"Rev Med Virol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2025.08.001","article-title":"High prevalence but low clinical impact of acyclovir-resistant herpes simplex virus type 1 infections in patients with hematologic disorders","volume":"59","author":"Chen CH","year":"2026","unstructured":"Chen CH, Chen LL, Su MC, Lin HH, Ho MW, Lin CW, Hsueh PR. High prevalence but low clinical impact of acyclovir-resistant herpes simplex virus type 1 infections in patients with hematologic disorders. J Microbiol Immunol Infect. 2026, 59:45-53. 10.1016\/j.jmii.2025.08.001","journal-title":"J Microbiol Immunol Infect"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.09.012","article-title":"Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey","volume":"100","author":"Burrel S","year":"2013","unstructured":"Burrel S, Aime C, Hermet L, Ait-Arkoub Z, Agut H, Boutolleau D. Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey. Antiviral Res. 2013, 100:365-372. 10.1016\/j.antiviral.2013.09.012","journal-title":"Antiviral Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104421","article-title":"Challenges of aciclovir-resistant HSV infection in allogeneic bone marrow transplant recipients","volume":"128","author":"Anton-Vazquez V","year":"2020","unstructured":"Anton-Vazquez V, Mehra V, Mbisa JL, et al.. Challenges of aciclovir-resistant HSV infection in allogeneic bone marrow transplant recipients. J Clin Virol. 2020, 128:104421. 10.1016\/j.jcv.2020.104421","journal-title":"J Clin Virol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix042","article-title":"Association of the emergence of acyclovir-resistant herpes simplex virus type 1 with prognosis in hematopoietic stem cell transplantation patients","volume":"215","author":"Kakiuchi S","year":"2017","unstructured":"Kakiuchi S, Tsuji M, Nishimura H, et al.. Association of the emergence of acyclovir-resistant herpes simplex virus type 1 with prognosis in hematopoietic stem cell transplantation patients. J Infect Dis. 2017, 215:865-873. 10.1093\/infdis\/jix042","journal-title":"J Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12227","article-title":"Predictors and outcomes of acyclovir-resistant herpes simplex virus infection among hematopoietic cell transplant recipients: case-case-control investigation","volume":"28","author":"Patel D","year":"2014","unstructured":"Patel D, Marchaim D, Marcus G, et al.. Predictors and outcomes of acyclovir-resistant herpes simplex virus infection among hematopoietic cell transplant recipients: case-case-control investigation. Clin Transplant. 2014, 28:1-5. 10.1111\/ctr.12227","journal-title":"Clin Transplant"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae638","article-title":"Refractory and resistant herpes simplex virus mucocutaneous infections in immunocompromised patients: literature review and proposed definitions for use in clinical trials","volume":"81","author":"Chemaly RF","year":"2025","unstructured":"Chemaly RF, Shafat T, Wald A, et al.. Refractory and resistant herpes simplex virus mucocutaneous infections in immunocompromised patients: literature review and proposed definitions for use in clinical trials. Clin Infect Dis. 2025, 81:593-601. 10.1093\/cid\/ciae638","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae046","article-title":"A multicenter assessment of the outcomes and toxicities of foscarnet for treatment of acyclovir-resistant mucocutaneous herpes simplex in immunocompromised patients","volume":"11","author":"Hammond SP","year":"2024","unstructured":"Hammond SP, Rangaraju M, Sumner M, Timmler B, Chandrasekar P, Avery RK. A multicenter assessment of the outcomes and toxicities of foscarnet for treatment of acyclovir-resistant mucocutaneous herpes simplex in immunocompromised patients. Open Forum Infect Dis. 2024, 11:ofae046. 10.1093\/ofid\/ofae046","journal-title":"Open Forum Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/tid.70162","article-title":"Acyclovir-resistant herpes simplex virus in pediatric patients undergoing allogeneic hematopoietic stem cell transplant: a case series","volume":"28","author":"Nunn J","year":"2026","unstructured":"Nunn J, Ahmed A, Senthil S, et al.. Acyclovir-resistant herpes simplex virus in pediatric patients undergoing allogeneic hematopoietic stem cell transplant: a case series. Transpl Infect Dis. 2026, 28:e70162. 10.1111\/tid.70162","journal-title":"Transpl Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.93215","article-title":"Atypical presentations of acyclovir-resistant herpes simplex virus in immunocompromised patients: a case series","volume":"17","author":"Allen K","year":"2025","unstructured":"Allen K, Wang A, Hibdon MA, Castro R, Greene J. Atypical presentations of acyclovir-resistant herpes simplex virus in immunocompromised patients: a case series. Cureus. 2025, 17:e93215. 10.7759\/cureus.93215","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13142","article-title":"Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant \u2014 a retrospective study","volume":"31","author":"Ariza-Heredia EJ","year":"2018","unstructured":"Ariza-Heredia EJ, Chemaly RF, Shahani LR, Jang Y, Champlin RE, Mulanovich VE. Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant \u2014 a retrospective study. Transpl Int. 2018, 31:639-648. 10.1111\/tri.13142","journal-title":"Transpl Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002269","article-title":"Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study","volume":"4","author":"Camargo JF","year":"2020","unstructured":"Camargo JF, Lin RY, Natori Y, et al.. Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study. Blood Adv. 2020, 4:4618-4622. 10.1182\/bloodadvances.2020002269","journal-title":"Blood Adv"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00615-10","article-title":"Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management","volume":"55","author":"Piret J","year":"2011","unstructured":"Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011, 55:459-472. 10.1128\/AAC.00615-10","journal-title":"Antimicrob Agents Chemother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.3.1085","article-title":"Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation","volume":"99","author":"Langston AA","year":"2002","unstructured":"Langston AA, Redei I, Caliendo AM, et al.. Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood. 2002, 99:1085-1088. 10.1182\/blood.v99.3.1085","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.28019","article-title":"Prevalence of immunosuppression among US adults","volume":"331","author":"Martinson ML","year":"2024","unstructured":"Martinson ML, Lapham J. Prevalence of immunosuppression among US adults. JAMA. 2024, 331:880-882. 10.1001\/jama.2023.28019","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2016.07.021","article-title":"The use of brincidofovir for the treatment of mixed dsDNA viral infection","volume":"83","author":"Camargo JF","year":"2016","unstructured":"Camargo JF, Morris MI, Abbo LM, et al.. The use of brincidofovir for the treatment of mixed dsDNA viral infection. J Clin Virol. 2016, 83:1-4. 10.1016\/j.jcv.2016.07.021","journal-title":"J Clin Virol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled Phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty FM","year":"2019","unstructured":"Marty FM, Winston DJ, Chemaly RF, et al.. A randomized, double-blind, placebo-controlled Phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019, 25:369-381. 10.1016\/j.bbmt.2018.09.038","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12582","article-title":"Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation","volume":"18","author":"Voigt S","year":"2016","unstructured":"Voigt S, Hofmann J, Edelmann A, Sauerbrei A, K\u00fchl JS. Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation. Transpl Infect Dis. 2016, 18:791-794. 10.1111\/tid.12582","journal-title":"Transpl Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01732-22","article-title":"Salvage treatment of refractory HSV oral lesions with pritelivir in allogeneic hematopoietic cell transplant recipients","volume":"67","author":"Bosetti D","year":"2023","unstructured":"Bosetti D, Bernardi C, Maulini M, et al.. Salvage treatment of refractory HSV oral lesions with pritelivir in allogeneic hematopoietic cell transplant recipients. Antimicrob Agents Chemother. 2023, 67:e0173222. 10.1128\/aac.01732-22","journal-title":"Antimicrob Agents Chemother"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2025.04.011","article-title":"Successful treatment and secondary prophylaxis with pritelivir for a recurrent multidrug-resistant herpes simplex virus 1 infection in an allogeneic haematopoietic stem cell transplant recipient","volume":"31","author":"Bussini L","year":"2025","unstructured":"Bussini L, Giardina AM, Paolucci S, Mannina D, Birkmann A, Bartoletti M. Successful treatment and secondary prophylaxis with pritelivir for a recurrent multidrug-resistant herpes simplex virus 1 infection in an allogeneic haematopoietic stem cell transplant recipient. Clin Microbiol Infect. 2025, 31:1234-1236. 10.1016\/j.cmi.2025.04.011","journal-title":"Clin Microbiol Infect"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac165","article-title":"Pritelivir for recurrent aciclovir-resistant herpes simplex virus 2 infections in immunocompromised patients","volume":"77","author":"Serris A","year":"2022","unstructured":"Serris A, Pouvaret A, Loiseau C, et al.. Pritelivir for recurrent aciclovir-resistant herpes simplex virus 2 infections in immunocompromised patients. J Antimicrob Chemother. 2022, 77:2303-2305. 10.1093\/jac\/dkac165","journal-title":"J Antimicrob Chemother"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/09564624211006568","article-title":"Use of pritelivir in refractory aciclovir-resistant herpes simplex virus type 2","volume":"32","author":"Cannon L","year":"2021","unstructured":"Cannon L, Tholouli E, Ward C, Farooq H, Kingston M. Use of pritelivir in refractory aciclovir-resistant herpes simplex virus type 2. Int J STD AIDS. 2021, 32:978-980. 10.1177\/09564624211006568","journal-title":"Int J STD AIDS"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf695.085","article-title":"233. Efficacy and safety results from the Phase 2 clinical trial of pritelivir versus foscarnet for treatment of acyclovir-refractory and\/or resistant mucocutaneous HSV infections in immunocompromised subjects","volume":"13","author":"Kotton CN","year":"2026","unstructured":"Kotton CN, Avery RK, Workowski K, et al.. 233. Efficacy and safety results from the Phase 2 clinical trial of pritelivir versus foscarnet for treatment of acyclovir-refractory and\/or resistant mucocutaneous HSV infections in immunocompromised subjects. Open Forum Infect Dis. 2026, 13:ofaf695.085. 10.1093\/ofid\/ofaf695.085","journal-title":"Open Forum Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.02.038","article-title":"Pritelivir demonstrated superior efficacy compared to investigator\u2019s choice treatment for refractory herpes simplex virus infections in immunocompromised patients: PRIOH-1, phase 3 safety and efficacy","volume":"32","author":"Papanicolaou G","year":"2026","unstructured":"Papanicolaou G, Avery R, Workowski K, et al.. Pritelivir demonstrated superior efficacy compared to investigator\u2019s choice treatment for refractory herpes simplex virus infections in immunocompromised patients: PRIOH-1, phase 3 safety and efficacy. Transplant Cell Ther. 2026, 32:S18-S19. 10.1016\/j.jtct.2026.02.038","journal-title":"Transplant Cell Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/ve\/veae101","article-title":"Combined use of pritelivir with acyclovir or foscarnet suppresses evolution of HSV-1 drug resistance","volume":"10","author":"Schalkwijk HH","year":"2024","unstructured":"Schalkwijk HH, Andrei G, Snoeck R. Combined use of pritelivir with acyclovir or foscarnet suppresses evolution of HSV-1 drug resistance. Virus Evol. 2024, 10:veae101. 10.1093\/ve\/veae101","journal-title":"Virus Evol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107169","article-title":"Amenamevir for treating acyclovir-resistant or refractory herpes simplex virus infection in allogeneic hematopoietic stem cell transplantation recipients: two case reports","volume":"63","author":"Sall\u00e9e L","year":"2024","unstructured":"Sall\u00e9e L, Souchet L, Boutolleau D, Nguyen S. Amenamevir for treating acyclovir-resistant or refractory herpes simplex virus infection in allogeneic hematopoietic stem cell transplantation recipients: two case reports. Int J Antimicrob Agents. 2024, 63:107169. 10.1016\/j.ijantimicag.2024.107169","journal-title":"Int J Antimicrob Agents"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.899","article-title":"Successful treatment of acyclovir-resistant herpes simplex virus infection with amenamevir in a patient who received umbilical cord blood transplantation for T-cell prolymphocytic leukemia","volume":"5","author":"Kawamura Y","year":"2024","unstructured":"Kawamura Y, Uchibori N, Arakawa T, et al.. Successful treatment of acyclovir-resistant herpes simplex virus infection with amenamevir in a patient who received umbilical cord blood transplantation for T-cell prolymphocytic leukemia. EJHaem. 2024, 5:616-619. 10.1002\/jha2.899","journal-title":"EJHaem"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.941864","article-title":"Adjunctive intravenous immunoglobulin and glucocorticoid therapy in severe herpes simplex encephalitis with excellent outcome begs for larger trials evaluating immunomodulatory therapy","volume":"25","author":"Sakoulas G","year":"2024","unstructured":"Sakoulas G, Roth J, Van der Kuy H. Adjunctive intravenous immunoglobulin and glucocorticoid therapy in severe herpes simplex encephalitis with excellent outcome begs for larger trials evaluating immunomodulatory therapy. Am J Case Rep. 2024, 25:e941864. 10.12659\/AJCR.941864","journal-title":"Am J Case Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54595-2","article-title":"Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years","volume":"15","author":"Neller MA","year":"2024","unstructured":"Neller MA, Ambalathingal GR, Hamad N, et al.. Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years. Nat Commun. 2024, 15:10339. 10.1038\/s41467-024-54595-2","journal-title":"Nat Commun"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011626","article-title":"Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol","volume":"8","author":"Nikiforow S","year":"2024","unstructured":"Nikiforow S, Whangbo JS, Reshef R, et al.. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Adv. 2024, 8:3001-3012. 10.1182\/bloodadvances.2023011626","journal-title":"Blood Adv"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00649-6","article-title":"Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial","volume":"25","author":"Mahadeo KM","year":"2024","unstructured":"Mahadeo KM, Baiocchi R, Beitinjaneh A, et al.. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. Lancet Oncol. 2024, 25:376-387. 10.1016\/S1470-2045(23)00649-6","journal-title":"Lancet Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2415","article-title":"Posoleucel, an allogeneic, off-the-shelf Multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting","volume":"29","author":"Pfeiffer T","year":"2023","unstructured":"Pfeiffer T, Tzannou I, Wu M, et al.. Posoleucel, an allogeneic, off-the-shelf Multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting. Clin Cancer Res. 2023, 29:324-330. 10.1158\/1078-0432.CCR-22-2415","journal-title":"Clin Cancer Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf125","article-title":"Transfer of herpes simplex virus type 1 (HSV-1) specific T cells in a pediatric patient post-HSCT with severe, acyclovir-resistant HSV-1 infection","volume":"82","author":"Wintering A","year":"2026","unstructured":"Wintering A, Bonifacius A, Tischer-Zimmermann S, et al.. Transfer of herpes simplex virus type 1 (HSV-1) specific T cells in a pediatric patient post-HSCT with severe, acyclovir-resistant HSV-1 infection. Clin Infect Dis. 2026, 82:366-369. 10.1093\/cid\/ciaf125","journal-title":"Clin Infect Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2010.047431","article-title":"Topical imiquimod treatment of aciclovir-resistant herpes simplex disease: case series and literature review","volume":"87","author":"Perkins N","year":"2011","unstructured":"Perkins N, Nisbet M, Thomas M. Topical imiquimod treatment of aciclovir-resistant herpes simplex disease: case series and literature review. Sex Transm Infect. 2011, 87:292-295. 10.1136\/sti.2010.047431","journal-title":"Sex Transm Infect"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3264-5","article-title":"Complex management of resistant oral herpes simplex virus infection following hematopoietic stem cell transplantation: potential role of topical cidofovir","volume":"24","author":"Epstein JB","year":"2016","unstructured":"Epstein JB, Gharapetian S, Rejali AR, Zabner R, Lill M, Tzachanis D. Complex management of resistant oral herpes simplex virus infection following hematopoietic stem cell transplantation: potential role of topical cidofovir. Support Care Cancer. 2016, 24:3603-3606. 10.1007\/s00520-016-3264-5","journal-title":"Support Care Cancer"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212448408","article-title":"Successful clearance of cutaneous acyclovir-resistant, foscarnet-refractory herpes virus lesions with topical cidofovir in an allogeneic hematopoietic stem cell transplant patient","volume":"19","author":"Muluneh B","year":"2013","unstructured":"Muluneh B, Dean A, Armistead P, Khan T. Successful clearance of cutaneous acyclovir-resistant, foscarnet-refractory herpes virus lesions with topical cidofovir in an allogeneic hematopoietic stem cell transplant patient. J Oncol Pharm Pract. 2013, 19:181-185. 10.1177\/1078155212448408","journal-title":"J Oncol Pharm Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/495022-refractory-andor-resistant-herpes-simplex-virus-mucocutaneous-infections-in-adult-transplantation-and-cellular-therapy-patients-a-single-center-experience","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:05:47Z","timestamp":1780419947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/495022-refractory-andor-resistant-herpes-simplex-virus-mucocutaneous-infections-in-adult-transplantation-and-cellular-therapy-patients-a-single-center-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.110131","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,2]]}}}